H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising obesity-drug program and its potential appeal to a deep-pocketed ...

In the past year, the stock has risen over 40% against the industry’s 11% decline. It has also outperformed the broader Medical sector and the S&P 500 Index. However, Viking’s shares are ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

Viking Therapeutics VKTX is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to ...

Now management is thinking about manufacturing tie-ups. Viking Therapeutics Inc.'s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company's promising obesity-drug ...